SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-23-019068
Filing Date
2023-09-14
Accepted
2023-09-14 18:57:13
Documents
2
Period of Report
2023-09-14

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 5407
2 EX-24 DOCUMENT attachment1.htm EX-24 5017
  Complete submission text file 0000899243-23-019068.txt   11908
Mailing Address C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949
Business Address
Fust Matthew K (Reporting) CIK: 0001397266 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-41802 | Film No.: 231256223

Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Issuer) CIK: 0001885522 (see all company filings)

IRS No.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences